News Details

Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies

About Editas Medicine, Inc.

Price Chart